163 related articles for article (PubMed ID: 29593410)
41. Preparation and in vivo safety evaluations of antileukemic homoharringtonine-loaded PEGylated liposomes.
Liu D; Xing J; Xiong F; Yang F; Gu N
Drug Dev Ind Pharm; 2017 Apr; 43(4):652-660. PubMed ID: 28005445
[TBL] [Abstract][Full Text] [Related]
42. Nanoliposome-mediated targeting of antibodies to tumors: IVIG antibodies as a model.
Nikpoor AR; Tavakkol-Afshari J; Gholizadeh Z; Sadri K; Babaei MH; Chamani J; Badiee A; Jalali SA; Jaafari MR
Int J Pharm; 2015 Nov; 495(1):162-170. PubMed ID: 26302860
[TBL] [Abstract][Full Text] [Related]
43. Determination of free and liposome-associated doxorubicin and vincristine levels in plasma under equilibrium conditions employing ultrafiltration techniques.
Mayer LD; St-Onge G
Anal Biochem; 1995 Dec; 232(2):149-57. PubMed ID: 8747469
[TBL] [Abstract][Full Text] [Related]
44. Liposomal and nonliposomal drug pharmacokinetics after administration of liposome-encapsulated vincristine and their contribution to drug tissue distribution properties.
Krishna R; Webb MS; St Onge G; Mayer LD
J Pharmacol Exp Ther; 2001 Sep; 298(3):1206-12. PubMed ID: 11504822
[TBL] [Abstract][Full Text] [Related]
45. The effect of vincristine-polyanion complexes in STEALTH liposomes on pharmacokinetics, toxicity and anti tumor activity.
Zhu G; Oto E; Vaage J; Quinn Y; Newman M; Engbers C; Uster P
Cancer Chemother Pharmacol; 1996; 39(1-2):138-42. PubMed ID: 8995511
[TBL] [Abstract][Full Text] [Related]
46. Enhanced anticancer efficacy of paclitaxel through multistage tumor-targeting liposomes modified with RGD and KLA peptides.
Sun J; Jiang L; Lin Y; Gerhard EM; Jiang X; Li L; Yang J; Gu Z
Int J Nanomedicine; 2017; 12():1517-1537. PubMed ID: 28280323
[TBL] [Abstract][Full Text] [Related]
47. Application of liposome encapsulation technique to improve anti-carcinoma effect of resveratrol.
Lu XY; Hu S; Jin Y; Qiu LY
Drug Dev Ind Pharm; 2012 Mar; 38(3):314-22. PubMed ID: 21851312
[TBL] [Abstract][Full Text] [Related]
48. Targeting vincristine plus tetrandrine liposomes modified with DSPE-PEG
Song XL; Liu S; Jiang Y; Gu LY; Xiao Y; Wang X; Cheng L; Li XT
Eur J Pharm Sci; 2017 Jan; 96():129-140. PubMed ID: 27644895
[TBL] [Abstract][Full Text] [Related]
49. Hierarchical self-assembly of heparin-PEG end-capped porous silica as a redox sensitive nanocarrier for doxorubicin delivery.
Nguyen Thi TT; Tran TV; Tran NQ; Nguyen CK; Nguyen DH
Mater Sci Eng C Mater Biol Appl; 2017 Jan; 70(Pt 2):947-954. PubMed ID: 27772725
[TBL] [Abstract][Full Text] [Related]
50. Magnetic field activated drug delivery using thermodegradable azo-functionalised PEG-coated core-shell mesoporous silica nanoparticles.
Saint-Cricq P; Deshayes S; Zink JI; Kasko AM
Nanoscale; 2015 Aug; 7(31):13168-13172. PubMed ID: 26181577
[TBL] [Abstract][Full Text] [Related]
51. Fluorescent Imaging Analysis for Distribution of Fluorescent Dye Labeled- or Encapsulated-Liposome in Monocrotaline-Induced Pulmonary Hypertension Model Rat.
Muraki Y; Yamasaki M; Takeuchi H; Tohyama K; Sano N; Matsuo T
Chem Pharm Bull (Tokyo); 2018 Mar; 66(3):270-276. PubMed ID: 29311495
[TBL] [Abstract][Full Text] [Related]
52. Preparation of pegylated nano-liposomal formulation containing SN-38: In vitro characterization and in vivo biodistribution in mice.
Atyabi F; Farkhondehfai A; Esmaeili F; Dinarvand R
Acta Pharm; 2009 Jun; 59(2):133-44. PubMed ID: 19564139
[TBL] [Abstract][Full Text] [Related]
53. [Preparation of liposome entrapped vincristine sulfate and mitoxantrone chlorhydric acid].
Chen T; Hou SX; Wang YY; Zhang WS; Shi BQ
Zhongguo Zhong Yao Za Zhi; 2007 Apr; 32(8):678-81. PubMed ID: 17608217
[TBL] [Abstract][Full Text] [Related]
54. Poly(ethylene glycol)-block-poly(ε-caprolactone)-and phospholipid-based stealth nanoparticles with enhanced therapeutic efficacy on murine breast cancer by improved intracellular drug delivery.
He X; Li L; Su H; Zhou D; Song H; Wang L; Jiang X
Int J Nanomedicine; 2015; 10():1791-804. PubMed ID: 25784805
[TBL] [Abstract][Full Text] [Related]
55. PEGylated liposomes of anastrozole for long-term treatment of breast cancer: in vitro and in vivo evaluation.
Shavi GV; Sreenivasa Reddy M; Raghavendra R; Nayak UY; Kumar AR; Deshpande PB; Udupa N; Behl G; Dave V; Kushwaha K
J Liposome Res; 2016; 26(1):28-46. PubMed ID: 25853340
[TBL] [Abstract][Full Text] [Related]
56. MRI-visible liposome nanovehicles for potential tumor-targeted delivery of multimodal therapies.
Ren L; Chen S; Li H; Zhang Z; Ye C; Liu M; Zhou X
Nanoscale; 2015 Aug; 7(30):12843-50. PubMed ID: 26022345
[TBL] [Abstract][Full Text] [Related]
57. Liposomal delivery of hydrophobic weak acids: enhancement of drug retention using a high intraliposomal pH.
Joguparthi V; Anderson BD
J Pharm Sci; 2008 Jan; 97(1):433-54. PubMed ID: 17918731
[TBL] [Abstract][Full Text] [Related]
58. Tat peptide and hexadecylphosphocholine introduction into pegylated liposomal doxorubicin: An in vitro and in vivo study on drug cellular delivery, release, biodistribution and antitumor activity.
Teymouri M; Badiee A; Golmohammadzadeh S; Sadri K; Akhtari J; Mellat M; Nikpoor AR; Jaafari MR
Int J Pharm; 2016 Sep; 511(1):236-244. PubMed ID: 27363937
[TBL] [Abstract][Full Text] [Related]
59. Vincristine and ɛ-viniferine-loaded PLGA-b-PEG nanoparticles: pharmaceutical characteristics, cellular uptake and cytotoxicity.
Öğünç Y; Demirel M; Yakar A; İncesu Z
J Microencapsul; 2017 Feb; 34(1):38-46. PubMed ID: 28084127
[TBL] [Abstract][Full Text] [Related]
60. Multifunctional upconversion mesoporous silica nanostructures for dual modal imaging and in vivo drug delivery.
Li C; Yang D; Ma P; Chen Y; Wu Y; Hou Z; Dai Y; Zhao J; Sui C; Lin J
Small; 2013 Dec; 9(24):4150-9. PubMed ID: 23843254
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
